D Giugliano1, P Chiodini2, M I Maiorino3, G Bellastella4, K Esposito3. 1. Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, Università della Campania Luigi Vanvitelli, Piazza L. Miraglia, 80131, Naples, Italy. dario.giugliano@unicampania.it. 2. Medical Statistics Unit, Department of Mental and Physical Health and Preventive Medicine, Università della Campania Luigi Vanvitelli, 80138, Naples, Italy. 3. Diabetes Unit, Department of Advanced Medical and Surgical Sciences, Università della Campania Luigi Vanvitelli, Piazza L. Miraglia, 80131, Naples, Italy. 4. Division of Endocrinology and Metabolic Diseases, Department of Advanced Medical and Surgical Sciences, Università della Campania Luigi Vanvitelli, Piazza L. Miraglia, 80131, Naples, Italy.
Abstract
PURPOSE: We did a meta-analysis with meta-regression to evaluate the relationship between hemoglobin A1c (A1C) reduction and the primary CV outcome of cardiovascular outcome trials (CVOTs). METHODS: We used a random effects meta-analysis of the 12 CVOTs to quantify the effect of A1C reduction on major cardiovascular events (MACE) risk by stratifying the difference in achieved A1C (drug vs placebo) in three strata: A1c < 0.3%, A1c ≥ 0.3% and < 0.5%, and A1c ≥ 0.5%. RESULTS: We found a relation between the reduction in achieved A1C and the hazard ratio reduction for MACE (P = 0.002), explaining almost all (94.1%) the between-study variances: lowering A1C by 0.5% conferred a significant HRR of 20% (95% CI 4-33%) for MACE. CONCLUSIONS: Blood glucose reduction may play a more important role than previously thought in reducing the risk of MACE during treatment with the newer glucose-lowering drugs, including peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors.
PURPOSE: We did a meta-analysis with meta-regression to evaluate the relationship between hemoglobin A1c (A1C) reduction and the primary CV outcome of cardiovascular outcome trials (CVOTs). METHODS: We used a random effects meta-analysis of the 12 CVOTs to quantify the effect of A1C reduction on major cardiovascular events (MACE) risk by stratifying the difference in achieved A1C (drug vs placebo) in three strata: A1c < 0.3%, A1c ≥ 0.3% and < 0.5%, and A1c ≥ 0.5%. RESULTS: We found a relation between the reduction in achieved A1C and the hazard ratio reduction for MACE (P = 0.002), explaining almost all (94.1%) the between-study variances: lowering A1C by 0.5% conferred a significant HRR of 20% (95% CI 4-33%) for MACE. CONCLUSIONS:Blood glucose reduction may play a more important role than previously thought in reducing the risk of MACE during treatment with the newer glucose-lowering drugs, including peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors.
Entities:
Keywords:
CVOTs (cardiovascular outcome trials); Glycemic control; Major cardiovascular events; Type 2 diabetes
Authors: M Angelyn Bethel; Rafael Diaz; Noelia Castellana; Indranil Bhattacharya; Hertzel C Gerstein; Mark C Lakshmanan Journal: Diabetes Care Date: 2021-01 Impact factor: 19.112
Authors: J Pepe; G Della Grotta; R Santori; V De Martino; M Occhiuto; M Cilli; S Minisola; C Cipriani Journal: J Endocrinol Invest Date: 2021-02-12 Impact factor: 4.256
Authors: Dario Giugliano; Lorenzo Scappaticcio; Miriam Longo; Paola Caruso; Maria Ida Maiorino; Giuseppe Bellastella; Antonio Ceriello; Paolo Chiodini; Katherine Esposito Journal: Cardiovasc Diabetol Date: 2021-09-15 Impact factor: 9.951